AR120512A1 - Formulaciones que contienen anticuerpos - Google Patents
Formulaciones que contienen anticuerposInfo
- Publication number
- AR120512A1 AR120512A1 ARP200103213A ARP200103213A AR120512A1 AR 120512 A1 AR120512 A1 AR 120512A1 AR P200103213 A ARP200103213 A AR P200103213A AR P200103213 A ARP200103213 A AR P200103213A AR 120512 A1 AR120512 A1 AR 120512A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- methods
- salt
- present disclosure
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 4
- 239000004475 Arginine Substances 0.000 abstract 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- 229930006000 Sucrose Natural products 0.000 abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000005720 sucrose Substances 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
En una realización no limitante, la presente divulgación se refiere a formulaciones liofilizadas que contienen un antagonista de IL-31 (por ejemplo, un anticuerpo anti-IL-31RA) como ingrediente activo, las formulaciones liofilizadas contienen además arginina y/o una sal de esta y sacarosa y/o trehalosa. En otra realización no limitante, la presente divulgación se refiere a formulaciones en solución que contienen un antagonista de IL-31 como ingrediente activo, conteniendo además las formulaciones en solución arginina y/o una sal de esta. En otras realizaciones no limitantes, la presente divulgación se refiere a métodos para estabilizar un anticuerpo (por ejemplo, un anticuerpo anti-IL-31RA) en una formulación que contiene anticuerpos, métodos para suprimir la agregación de anticuerpos (formación de agregados) en una formulación que contiene anticuerpo, y métodos para reducir componentes con heterogeneidad de carga en una formulación que contiene anticuerpos, caracterizados los métodos porque la formulación se prepara para contener arginina y/o una sal de esta, y/o sacarosa y/o trehalosa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019209851 | 2019-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR120512A1 true AR120512A1 (es) | 2022-02-16 |
Family
ID=75981291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200103213A AR120512A1 (es) | 2019-11-20 | 2020-11-19 | Formulaciones que contienen anticuerpos |
Country Status (13)
Country | Link |
---|---|
US (3) | US11260125B2 (es) |
EP (1) | EP4062933A4 (es) |
JP (4) | JP6845973B1 (es) |
KR (2) | KR20220098046A (es) |
CN (1) | CN114728064A (es) |
AR (1) | AR120512A1 (es) |
AU (1) | AU2020387034A1 (es) |
BR (1) | BR112022006590A2 (es) |
CA (1) | CA3156713A1 (es) |
IL (1) | IL293099A (es) |
MX (1) | MX2022005654A (es) |
TW (1) | TW202128222A (es) |
WO (1) | WO2021100794A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202327654A (zh) | 2015-04-14 | 2023-07-16 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 |
JP6845973B1 (ja) | 2019-11-20 | 2021-03-24 | 中外製薬株式会社 | 抗体含有製剤 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5043008Y2 (es) | 1972-08-19 | 1975-12-09 | ||
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JP2898064B2 (ja) | 1989-08-03 | 1999-05-31 | 忠三 岸本 | ヒトgp130蛋白質 |
GB9016440D0 (en) | 1990-07-26 | 1990-09-12 | Elopak Systems | A laminate |
BR9204244A (pt) | 1992-10-26 | 1994-05-03 | Cofap | Ferro fundido cinzento |
CZ140195A3 (en) | 1992-12-01 | 1996-06-12 | Protein Desing Labs | Humanized antibodies reacting with l-selectin |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
FR2729855A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
WO1997010354A1 (en) | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
CN1241944A (zh) | 1996-12-05 | 2000-01-19 | 乔治敦大学 | 具有抗病毒活性的鼠尾草种类的提取物 |
JPH11101542A (ja) | 1997-09-29 | 1999-04-13 | Sanyo Electric Co Ltd | 冷蔵庫 |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
CA2326755A1 (en) | 1998-04-30 | 1999-11-04 | Tanox, Inc. | G-csf receptor agonist antibodies and screening method therefor |
FR2780062B1 (fr) | 1998-06-17 | 2000-07-28 | Rhone Poulenc Rorer Sa | Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations |
WO1999067290A1 (fr) | 1998-06-24 | 1999-12-29 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelles proteines receptrices d'hemopoïetine |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
ES2339843T3 (es) | 1999-06-02 | 2010-05-26 | Chugai Seiyaku Kabushiki Kaisha | Proteina receptora de hematopoyetina novedosa, nr10. |
ES2254224T3 (es) | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
CN1326880A (zh) | 2000-06-06 | 2001-12-19 | 周伟中 | 双层站台火车站 |
WO2002000721A2 (en) | 2000-06-26 | 2002-01-03 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
US20030096339A1 (en) | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
AU2002213251B2 (en) | 2000-10-16 | 2007-06-14 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
WO2002077230A1 (fr) | 2001-03-26 | 2002-10-03 | Chugai Seiyaku Kabushiki Kaisha | Variants d'epissage nr10 |
WO2002081522A1 (fr) | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
BR0306979A (pt) | 2002-01-18 | 2004-11-23 | Zymogenetics Inc | Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente |
AU2003280410B8 (en) | 2002-01-18 | 2009-04-23 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
SI1485477T1 (sl) | 2002-02-25 | 2009-10-31 | Genentech Inc | Novi citokinski receptor GLM-R tipa 1 |
US7579000B2 (en) | 2002-05-01 | 2009-08-25 | Bayer Schering Pharma Ag | Tissue factor targeted antibodies as anticoagulants |
CA2483909A1 (en) | 2002-05-01 | 2003-11-13 | Schering Aktiengesellschaft | Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
TW200407335A (en) | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
KR100499989B1 (ko) | 2002-12-27 | 2005-07-07 | 네오바이오다임 주식회사 | 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법 |
US20040223970A1 (en) | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
ES2527414T3 (es) | 2003-03-04 | 2015-01-23 | Alexion Pharmaceuticals, Inc. | Método para el tratamiento de una enfermedad autoinmune mediante la inducción de la presentación de antígeno mediante células presentadoras de antígeno que inducen tolerancia |
EA009124B1 (ru) | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении |
ZA200606461B (en) | 2004-02-12 | 2008-02-27 | Lexicon Pharmaceuticals Inc | Gene disruptions, compositions and methods relating thereto |
KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
AU2005259992A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune, Llc | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
AU2006207945B2 (en) | 2005-01-28 | 2012-02-09 | Zymogenetics, Inc. | Homogeneous preparations of IL-31 |
WO2006088855A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
EP1856539B1 (en) | 2005-02-14 | 2015-10-21 | ZymoGenetics, Inc. | Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
ES2561628T3 (es) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y métodos de uso |
EP3348639A3 (en) | 2005-06-10 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Sc(fv)2 site-directed mutant |
CA2636288C (en) | 2006-01-10 | 2015-02-24 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
RU2520088C2 (ru) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Антитела к ох-2/сd200 и их применение |
MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
DK2047863T3 (da) | 2006-06-08 | 2013-09-16 | Chugai Pharmaceutical Co Ltd | Middel til forebyggelse eller behandling af inflammatoriske sygdomme |
ES2415655T3 (es) | 2006-06-15 | 2013-07-26 | The Board Of Trustees Of The University Of Arkansas | Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina |
SI2594586T1 (sl) | 2006-09-01 | 2014-11-28 | Zymogenetics, Inc. | IL-31 monoklonska protitelesa in metode uporabe |
CN101600456A (zh) | 2006-12-11 | 2009-12-09 | 惠氏公司 | 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物 |
WO2008073463A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
WO2009007272A1 (en) | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
AR068564A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti- receptor de il-6 (interleuquina 6) |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
MX337081B (es) * | 2007-12-05 | 2016-02-10 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-nr10 y su uso. |
CN101939025B (zh) | 2007-12-05 | 2015-03-25 | 中外制药株式会社 | 搔痒症治疗药 |
KR101603109B1 (ko) * | 2007-12-07 | 2016-03-25 | 지모제넥틱스, 인코포레이티드 | Il-31에 특이적인 인간화된 항체 분자 |
KR20160062207A (ko) | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항nr10 항체 및 그의 이용 |
JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
EP3679942A1 (en) | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
EP2735315B1 (en) * | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
JP5650871B1 (ja) | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のil−31アンタゴニストによる治療に対する応答を予測する方法 |
TW202327654A (zh) | 2015-04-14 | 2023-07-16 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物 |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
GB201703063D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
MX2019012255A (es) * | 2017-04-11 | 2019-12-05 | Kiniksa Pharmaceuticals Ltd | Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr). |
WO2019225568A1 (ja) * | 2018-05-21 | 2019-11-28 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
JP6845973B1 (ja) | 2019-11-20 | 2021-03-24 | 中外製薬株式会社 | 抗体含有製剤 |
-
2020
- 2020-11-19 JP JP2020565503A patent/JP6845973B1/ja active Active
- 2020-11-19 WO PCT/JP2020/043125 patent/WO2021100794A1/ja unknown
- 2020-11-19 EP EP20889058.2A patent/EP4062933A4/en active Pending
- 2020-11-19 KR KR1020227021869A patent/KR20220098046A/ko active Application Filing
- 2020-11-19 CA CA3156713A patent/CA3156713A1/en active Pending
- 2020-11-19 MX MX2022005654A patent/MX2022005654A/es unknown
- 2020-11-19 AU AU2020387034A patent/AU2020387034A1/en active Pending
- 2020-11-19 TW TW109140495A patent/TW202128222A/zh unknown
- 2020-11-19 AR ARP200103213A patent/AR120512A1/es unknown
- 2020-11-19 IL IL293099A patent/IL293099A/en unknown
- 2020-11-19 BR BR112022006590A patent/BR112022006590A2/pt unknown
- 2020-11-19 CN CN202080080856.8A patent/CN114728064A/zh active Pending
- 2020-11-19 KR KR1020207035525A patent/KR102416078B1/ko active IP Right Grant
-
2021
- 2021-02-26 JP JP2021029739A patent/JP6889344B2/ja active Active
- 2021-05-20 JP JP2021085001A patent/JP2021169448A/ja not_active Withdrawn
- 2021-06-14 US US17/346,421 patent/US11260125B2/en active Active
-
2022
- 2022-01-12 US US17/573,991 patent/US11723976B2/en active Active
- 2022-03-04 US US17/686,536 patent/US20220184210A1/en active Pending
- 2022-06-06 JP JP2022091316A patent/JP2022116305A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL293099A (en) | 2022-07-01 |
US11723976B2 (en) | 2023-08-15 |
MX2022005654A (es) | 2022-06-22 |
CA3156713A1 (en) | 2021-05-27 |
US20220125921A1 (en) | 2022-04-28 |
US20220184210A1 (en) | 2022-06-16 |
KR102416078B1 (ko) | 2022-07-01 |
WO2021100794A1 (ja) | 2021-05-27 |
JPWO2021100794A1 (ja) | 2021-12-02 |
KR20210064112A (ko) | 2021-06-02 |
US11260125B2 (en) | 2022-03-01 |
CN114728064A (zh) | 2022-07-08 |
JP2022116305A (ja) | 2022-08-09 |
AU2020387034A1 (en) | 2022-06-02 |
JP2021169448A (ja) | 2021-10-28 |
TW202128222A (zh) | 2021-08-01 |
JP6889344B2 (ja) | 2021-06-18 |
US20210322550A1 (en) | 2021-10-21 |
BR112022006590A2 (pt) | 2022-06-28 |
JP2021091704A (ja) | 2021-06-17 |
KR20220098046A (ko) | 2022-07-08 |
EP4062933A1 (en) | 2022-09-28 |
EP4062933A4 (en) | 2023-12-13 |
JP6845973B1 (ja) | 2021-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17034829A (es) | Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
ECSP099642A (es) | Formulaciones estables de anticuerpo | |
AR120512A1 (es) | Formulaciones que contienen anticuerpos | |
AR095396A1 (es) | Formulaciones de anticuerpo | |
AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
BR112012018023A2 (pt) | formulações líquidas que contêm anticorpo estabilizado. | |
NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
CL2023002505A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas | |
EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
AR115713A1 (es) | FORMULACIÓN ESTABLE DE ALTA CONCENTRACIÓN PARA ANTICUERPOS ANTI-FXIa | |
AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
BR112022006222A2 (pt) | Formulação farmacêutica estável de um anticorpo a4ss7, e, método para controlar agregados e variantes de carga de um anticorpo a4ss7 |